세계의 호흡기 질환 백신 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 감염증별, 연령층별, 유통 채널별, 지역별, 부문 예측(2025-2030년)

Respiratory Disease Vaccine Market Growth & Trends:

The respiratory disease vaccine market size is estimated to reach USD 70.30 billion by 2030, expanding at a CAGR of 2.90% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the respiratory disease vaccine market is attributable to increasing awareness associated with the importance of vaccination, the rising incidence of respiratory infections, and advancements in vaccine technology. Moreover, the COVID-19 pandemic has brought significant traction to the importance of respiratory vaccines which has further accelerated the market.

Respiratory vaccines, particularly those targeting influenza and pneumonia, are vital in reducing the burden on healthcare systems and minimizing the risk of co-infections with COVID-19. In order to prevent the spread of the virus and prevent the occurrence of outbreaks healthcare providers have been focusing on vaccination to protect individuals against respiratory pathogens like influenza. In recent years, the respiratory vaccine market has witnessed substantial growth attributed to advancements in vaccine technology, specifically in the development of vaccines targeting SARS-CoV-2. The successful development, approval, and deployment of COVID-19 vaccines have demonstrated the capacity of the scientific community to respond rapidly to respiratory threats and have paved the way for future advancements in respiratory vaccine research and development.

Moreover, government backing and surveillance at both national and global levels to monitor the availability, dissemination, and implementation of influenza vaccines is a crucial factor driving the growth of the market. Additionally, increased investments by prominent key players with a major focus on the introduction of novel vaccines into the market have contributed to the growth of the market. For instance, Pfizer recently disclosed their plans to commence Phase 3 clinical trials for their mRNA-based influenza vaccine in September 2022. This trial will involve a cohort of 25,000 individuals aged 18 and above from the U.S.

Furthermore, key players involved in developing and formulating various respiratory disease vaccines are focusing on collaborations and partnerships to develop novel vaccines and to maintain their competitive position in the market. In addition, increasing interest in plant-based medicines owing to natural remedies offered by them is expected to boost the market over the forecast period. Moreover, a number of players are involved in geographic expansion and distribution to meet the rising demand for medicinal products. For instance, in May 2023, Pfizer Inc. received FDA approval for ABRYSVO, a RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in the elderly population above the age of 60 years.

Respiratory Disease Vaccine Market Report Highlights:

• Based on type, the viral vaccine segment held the largest market share of 54.84% in 2024 owing to the increasing prevalence of viral respiratory conditions
• Based on age group, the pediatric segment is expected to show the fastest growth rate over the forecast period owing to the rising formulation of vaccines for the pediatric population
• On the basis of infection, The COVID-19 segment held the largest market share of 40.03% in 2024 due to the growing need for the development of a vaccine to stop the spread of the COVID-19 virus
• Key players operating in the market are constantly focusing on geographical expansion and product launches to maintain their presence
• North America's respiratory disease vaccine market is expected to grow strongly over the forecast period which can be attributed to the presence of key players, rising healthcare infrastructure, growing cases of chronic disorders, and availability of proper vaccination service

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Respiratory Disease Vaccine Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. Respiratory Disease Vaccine Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Respiratory Disease Vaccine Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Respiratory Disease Vaccine Market: Type Movement Analysis, 2024 & 2030 (USD Million)
• 4.3. Viral Vaccine
  • 4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Bacterial Vaccine
  • 4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Combination Vaccine
  • 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Respiratory Disease Vaccine Market: Age Group Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Respiratory Disease Vaccine Market: Age Group Movement Analysis, 2024 & 2030 (USD Million)
• 5.3. Pediatric
  • 5.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Adult
  • 5.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Respiratory Disease Vaccine Market: Infection Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Respiratory Disease Vaccine Market: Infection Movement Analysis, 2024 & 2030 (USD Million)
• 6.3. COVID-19
  • 6.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Influenza
  • 6.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Respiratory Syncytial Virus (RSV)
  • 6.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Pneumonia
  • 6.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Respiratory Disease Vaccine Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Respiratory Disease Vaccine Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
• 7.3. Hospital & Retail Pharmacies
  • 7.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Government Suppliers
  • 7.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Others
  • 7.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Respiratory Disease Vaccine Market: Regional Estimates & Trend Analysis

• 8.1. Respiratory Disease Vaccine Market Share, By Region, 2024 & 2030, USD Million
• 8.2. North America
  • 8.2.1. North America Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. U.S. Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.3. Canada
    • 8.2.3.1. Canada Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.4. Mexico
    • 8.2.4.1. Mexico Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.3. Europe
  • 8.3.1. Europe Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. UK Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.3. Germany
    • 8.3.3.1. Germany Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.4. France
    • 8.3.4.1. France Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.5. Italy
    • 8.3.5.1. Italy Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.6. Spain
    • 8.3.6.1. Spain Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.7. Denmark
    • 8.3.7.1. Denmark Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.8. Sweden
    • 8.3.8.1. Sweden Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.9. Norway
    • 8.3.9.1. Norway Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Japan Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. China
    • 8.4.3.1. China Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. India
    • 8.4.4.1. India Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.5. Australia
    • 8.4.5.1. Australia Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.6. South Korea
    • 8.4.6.1. South Korea Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.7. Thailand
    • 8.4.7.1. Thailand Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Latin America
  • 8.5.1. Latin America Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Brazil Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Argentina
    • 8.5.3.1. Argentina Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Middle East and Africa
  • 8.6.1. Middle East and Africa Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. South Africa Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. South Africa Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. UAE
    • 8.6.4.1. UAE Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.5. Kuwait
    • 8.6.5.1. Kuwait Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis by Key Market Participants
• 9.2. Company Categorization
• 9.3. Company Heat Map Analysis
• 9.4. Company Profiles
  • 9.4.1. GSK plc.
    • 9.4.1.1. Participant's Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Recent Developments/ Strategic Initiatives
  • 9.4.2. Johnson & Johnson Services, Inc.
    • 9.4.2.1. Participant's Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Recent Developments/ Strategic Initiatives
  • 9.4.3. Pfizer Inc.
    • 9.4.3.1. Participant's Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Recent Developments/ Strategic Initiatives
  • 9.4.4. Sanofi
    • 9.4.4.1. Participant's Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Recent Developments/ Strategic Initiatives
  • 9.4.5. Serum Institute of India Pvt. Ltd.
    • 9.4.5.1. Participant's Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Recent Developments/ Strategic Initiatives
  • 9.4.6. SINOVAC
    • 9.4.6.1. Participant's Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Recent Developments/ Strategic Initiatives
  • 9.4.7. Bavarian Nordic
    • 9.4.7.1. Participant's Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Recent Developments/ Strategic Initiatives
  • 9.4.8. Merck & Co., Inc.
    • 9.4.8.1. Participant's Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Recent Developments/ Strategic Initiatives
  • 9.4.9. AstraZeneca
    • 9.4.9.1. Participant's Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Recent Developments/ Strategic Initiatives
  • 9.4.10. EMERGENT
    • 9.4.10.1. Participant's Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Recent Developments/ Strategic Initiatives
  • 9.4.11. Novavax
    • 9.4.11.1. Participant's Overview
    • 9.4.11.2. Financial Performance
    • 9.4.11.3. Product Benchmarking
    • 9.4.11.4. Recent Developments/ Strategic Initiatives
  • 9.4.12. INOVIO Pharmaceuticals
    • 9.4.12.1. Participant's Overview
    • 9.4.12.2. Financial Performance
    • 9.4.12.3. Product Benchmarking
    • 9.4.12.4. Recent Developments/ Strategic Initiatives
  • 9.4.13. Moderna, Inc.
    • 9.4.13.1. Participant's Overview
    • 9.4.13.2. Financial Performance
    • 9.4.13.3. Product Benchmarking
    • 9.4.13.4. Recent Developments/ Strategic Initiatives